Skin Diseases
Conditions
Brief summary
Forty-five participants with facial AV were assigned randomly to three groups of fifteen subjects each. Each group received various therapies. Group A (Study group A) had received both NBUB and akne-Mycin; Group B( study group B) had received Red LLLT and akne-Mycin and group C (Control group) received only akne-Mycin cream. All 45 participants are tested at the initial treatments, after 4 weeks and after 8 weeks by the acne count, the intensity scale and the photographic test.
Detailed description
Forty-five patient (18 male and 27 female) were recruited on a referral basis from the department of dermatology at Kasr Al- aini Teaching Hospital. Firstly, an interview was held with each participant to determine gender, age, skin type, acne severity and medical prescriptions,Randomization was performed by selecting numbers from opaque envelopes containing numbers that were chosen by a random number generator, selection was done by an independent person. Patients in group (A) received a program of NBUB, ( DIXWELL EMLY 98 -ABRP 64 ,made in France) wavelength 311 to 313nm , in addition to topical aknemycin medications. Each treatment lasts one to eight minutes. The treatments were given three times a week. for 8 weeks.Participants in-group (B) received a program of R-LLLT that was conducted through laser equipment InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia) with fluence 12 J/cm2, two sessions per week for 8 weeks .Patients in the three groups were asked to apply topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period .Evaluation was based on formal counts of active lesions (papule and pustule).facial photographs using a digital camera (PANASONIC, Tokyo, Japan). and Five-point scale of investigators assessment that reflect lesion count improved percentage.
Interventions
DEVICENarrow band ultraviolet B.
NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
DRUGtopical erythromycin cream 2% (Akne-Mycin- Egypt)
two times per day on the entire face from the beginning to the end of the treatment period . The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The present study is a pretest-post test single blind randomized controlled trial, conducted at Faculty of Physical Therapy, Cairo University.
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Ages ranged from 18-35 years. * Skin type III and IV. * Mild to moderate facial acne.
Exclusion criteria
* Treatment with oral retinoid within past 1 year. * Treatment with other acne treatment within past 3 months. * History of treatment with systemic and topical antibiotics for acne vulgaris within the last 1 month. * Treatment with oral isotretinoin within the last 6 months. * Participants received radiotherapy or chemotherapy. * Any history of photosensitivity. * Chemical peels during the previous 4 weeks. * Seizures, * Pregnancy * Use of oral contraceptives. * Breastfeeding .
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| formal counts of active acne lesions. | 8 weeks. | The lesion number was individually counted by lesion type at all three times of evaluation as the number of papules and pustules |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| facial photographic method. | 8 weeks. | facial photographs using a digital camera (PANASONIC, Tokyo, Japan). Photos of the front and bilateral sides of the face were clinically taken each time, by same manner at all time points. |
Other
| Measure | Time frame | Description |
|---|---|---|
| lesion count changed percentage. | 8 weeks. | Five-point scale of investigators assessment that reflect lesion count changed percentage; worse: \< - 10 percent, no change:\_9percent-9percent, mild improvement: 10percent-39percent, moderate improvement: 40percent-59percent, marked improvement: 60percent-89percent, and clearance: ≥-90percent. |
Countries
Egypt
Outcome results
None listed